Company news

Arcturus Therapeutics Holdings Inc. news in 2021

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2021, newest first.

View company

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

December 15, 2021

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

December 12, 2021

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

November 21, 2021

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

November 7, 2021

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

October 24, 2021

Arcturus Therapeutics Announces Leadership Appointments

October 20, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

October 11, 2021

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

September 21, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

September 21, 2021

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

September 7, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

September 6, 2021

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

August 8, 2021

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

August 2, 2021

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

August 1, 2021

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

August 1, 2021

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

July 27, 2021

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

July 25, 2021

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

May 9, 2021

Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

May 2, 2021

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

February 28, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

February 21, 2021

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

February 18, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conferences

February 10, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conference

January 5, 2021

Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

January 3, 2021

Calls in 2021

Decks in 2021